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Background: Type 2 diabetes mellitus is a major global public health problem in the worldwide and is increasing
in aging populations. Magnesium intake may be one of the most important factors for diabetes prevention and
management. Low magnesium intake may exacerbate metabolic abnormalities. In this study, the relationships of
magnesium intake with metabolic parameters, depression and physical activity in elderly patients with type 2
diabetes were investigated.
Methods: This cross-sectional study involved 210 type 2 diabetes patients aged 65 years and above. Participants
were interviewed to obtain information on lifestyle and 24-hour dietary recall. Assessment of depression was based
on DSM-IV criteria. Clinical variables measured included anthropometric measurements, blood pressure, and
biochemical determinations of blood and urine samples. Linear regression was applied to determine the
relationships of magnesium intake with nutritional variables and metabolic parameters.
Results: Among all patients, 88.6% had magnesium intake which was less than the dietary reference intake, and
37.1% had hypomagnesaemia. Metabolic syndromes and depression were associated with lower magnesium intake
(p< 0.05). A positive relationship was found between magnesium intake and HDL-cholesterol (p= 0.005).
Magnesium intake was inversely correlated with triglyceride, waist circumference, body fat percent and body mass
index (p< 0.005). After controlling confounding factor, HDL-cholesterol was significantly higher with increasing
quartile of magnesium intake (p for trend = 0005). Waist circumference, body fat percentage, and body mass index
were significantly lower with increase quartile of magnesium intake (p for trend< 0.001). The odds of depression,
central obesity, high body fat percentage, and high body mass index were significantly lower with increasing
quartile of magnesium intake (p for trend< 0.05). In addition, magnesium intake was related to high physical
activity level and demonstrated lower serum magnesium levels. Serum magnesium was not significantly associated
with metabolic parameters.
Conclusions: The majority of elderly type 2 diabetes who have low magnesium intake may compound this
deficiency with metabolic abnormalities and depression. Future studies should determine the effects of increased
magnesium intake or magnesium supplementation on metabolic control and depression in elderly people with
type 2 diabetes.
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Type 2 diabetes mellitus (DM) is a major public health
problem in the worldwide and is increasing in aging
populations [1,2]. Moreover, type 2 DM is a significant
cause of premature mortality and morbidity related to
cardiovascular disease, macrovascular complications,
and microvascular complications in older adults [3-5].
The optimal goal of management in DM is to achieve
and maintain adequate blood glucose, blood lipids, and
blood pressure levels to prevent or delay chronic compli-
cations of diabetes. Elderly patients with diabetes can
achieve adequate metabolic control by following a nutri-
tion plan and an exercise program, losing excess weight,
complying with a self-management education interven-
tion program and taking appropriate medications [6].
Magnesium may be one of the most important factors
for diabetes prevention and management [7,8]. Indeed,
magnesium has been associated with a number of
chronic disease including, diabetes, hypertension, insulin
resistance and lipid abnormalities [9]. Magnesium defi-
ciency (1) is a common factor associated with insulin re-
sistance and vascular disease [10], (2) impairs energy
metabolism efficiency and reduces the capacity for phys-
ical work [11], (3) exerts negative effects on blood glu-
cose homeostasis [12], and (4) is independently
associated with depressive symptoms [13]. In addition,
magnesium intake was inversely associated with the
metabolic syndrome and risk of type 2 DM [8,14]. High
plasma triglycerides, abdominal adiposity, albuminuria
and low HDL-cholesterol are associated with hypomag-
nesemia in diabetic patients [15,16]. Double-blind
placebo-controlled trials suggest magnesium supplemen-
tation may (1) improve insulin sensitivity, reduce of
plasma cholesterol and LDL cholesterol, increase of
HDL cholesterol in DM patients [7,17] (2) lower blood
pressure in patients with essential hypertension [18], and
(3) improve resting ionic magnesium levels in physically
active women [19]. Furthermore, magnesium supple-
mentation has been shown to be as effective as an anti-
depressant drug for treatment of depression in the
elderly DM patients with hypomagnesemia [20].
Assessment of magnesium status is important for de-
termining the association of magnesium with metabolic
control and cardiovascular disease. A simple method
available in a clinical setting is the measurement of
serum magnesium. However, serum magnesium levels
correlate poorly with magnesium status [21]. The deter-
mination of intracellular magnesium levels from muscle
biopsy, lymphocytes, and red blood cells is a much bet-
ter predictor of magnesium status via nuclear magnetic
resonance spectroscopy or ion-specific electrode mea-
sures [22]. These tests are of value in basic research;
however, they are expensive and impractical. Several
studies showed that magnesium intake is associated withdiabetes risk, metabolic control and cardiovascular dis-
ease [8,14,23]. In general, assessment of magnesium in-
take may be not accurate. However, a more effective
assessment of dietary intake can be achieved through
improved methodology and interview, and such evalua-
tions offer the advantage of being non-invasive [24].
Numerous clinical studies on magnesium supplemen-
tation have suggested that dietary magnesium deficiency
may impair metabolic control [10,25]. However, various
studies of magnesium intakes and magnesium supple-
mentation were inconsistent [7,17]. Indeed, dietary mag-
nesium intake in elderly patients with diabetes and its
relationship to metabolic control, depression and phys-
ical activity have not been intensively explored.
The present study was conducted to investigate mag-
nesium status in elderly type 2 diabetes patients and to
determine its relationship with nutritional variables,
metabolic control, depression and physical activity. In
this cross-sectional study, information about dietary in-
take, physical activity, and depression were obtained by
questionnaires. In additional, anthropometric values, as
well as biochemical determinations of blood and urine
samples were also investigated.
Subjects and methods
Study subjects
The cross-sectional study was approved by the Chan-
ghua Christian Hospital Institutional Review Board
(CCHIRB#090419). Patients were residents in a rural
area of central Taiwan, and diabetes at the first the
Endocrine and Metabolism clinic was diagnosed accord-
ing to the American Diabetes Association (ADA) criteria
[26]: 1). fasting plasma glucose (FPG) ≧126 mg/dL. Fast-
ing is defined as no caloric intake for at least 8 h. OR 2).
2-h plasma glucose ≧200 mg/dL during an oral glucose
tolerance test (OGTT). OR 3). in a patient with classic
symptoms of hyperglycemia or hyperglycemic crisis, a
random plasma glucose≧200 mg/dL. In general, patients
with type 2 diabetes commonly have components of
metabolic syndrome (e.g. dyslipidemia and hyperten-
sion). The medication use is following the Taiwan Dia-
betes Clinical Care Guideline, the ADA standards of
medical care in diabetes [27] and the National Choles-
terol Education Program (NCEP) Expert Panel on Detec-
tion, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III)
[28,29]. The inclusion criteria for patients were as fol-
lows: 1) Type 2 diabetes for more than 6 months; 2) no
change in any medications for the past 3 months; 3)
stable lifestyle for the past 3 months; and; 4) aged
65 years and above. Patients with heart failure, cirrhosis,
current malignancy, chronic renal failure, or signs of ser-
ious deterioration in comprehension and memory were
excluded. Anthropometric measurements, biochemical
Huang et al. Nutrition Journal 2012, 11:41 Page 3 of 10
http://www.nutritionj.com/content/11/1/41blood and urine tests, as well as dietary assessment were
performed within one month. For elderly patients with a
low level of education and who were unable to write
their signature, children or family members signed con-
sent forms on their behalf.
Dietary assessment
Dietary intake was assessed using 24-hour recall [24,30].
In addition, questionnaires of typical dietary pattern
were also applied in the survey to assess subjects’ daily
dietary intake. The 24-h dietary recalls and a week of
typical dietary pattern were collected via interview by a
registered dietitian. During the interview, quantitative
tools including standard measuring spoons and cups,
food models, food pictures and photos, and traditional
household bowls, cups and spoons were used to help the
these elderly subjects [31]. Magnesium and other nutri-
ents intake were analyzed using Taiwan Nutrition Data-
base and the EKitchen nutritional analysis software
(Nutritional Chamberlain Line, Professional Edition, ver-
sion 2001/ 2003, EKitchen Inc, Taichung, Taiwan) [32].
Taiwan Dietary Reference Intakes (DRI) for magnesium
in adults and elderly person was based on the U.S.A.
EAR of 5 mg/kg/day [33] and Taiwanese reference body
weight. Therefore, Taiwan DRI of magnesium for health
individuals above 19 years of age is 360 mg/d for males
and 315 mg/d for females. Taiwan RDA for protein in
elderly person is 1 g//kg/day [34]. In this study, we
divided protein intake into 3 categories and defined the
following ranges: < 0.8, 0.8 to 1.0, > 1.0 g//kg. In
addition, the Taiwan Resting Energy Expenditure (REE)
for energy in aged 65 years and above is 22 kcal/kg/day
for men or 20 kcal/kg/day for women. We referred to
Taiwan REE and estimated energy requirement divided
energy intake into 3 categories and defined the following
ranges: < 25, 25 to 30, >30 kcal//kg.
Assessment of physical activity
Assessment of physical activity is based on a slightly
modified version of the method using in a Finnish study
[35]. Briefly, occupational physical activity was divided
into: 1) light: physically very easy, seated office work; 2)
moderate: work including standing and walking; and 3)
active: work including walking and lifting, or heavy
manual labor. Daily commuting journey was categorized
into: 1) using motorized transportation, or no work; 2)
walking or bicycling 1–29 min; and 3) walking or bicyc-
ling> 30 min. Self-reported leisure-time physical activity
was classified into: 1) low: almost completely inactive;
2) moderate: some physical activity >4 h per week; and
3) high: vigorous physical activity> 3 h per week. Phys-
ical activities were accumulated and regrouped into: 1)
low; 2) moderate and 3) high according to the Finnish
study [35].Assessment of depression
Assessment of depression was based on the criteria in
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition (DSM-IV), and included the number
and severity of symptoms, duration of the current epi-
sode, and course of illness. Depression was diagnosed
in patients with 5 or more symptoms including at least
one key symptom, most days, most of the time for at
least 2 weeks, as defined by the American Psychiatric
Association [36].
Biochemical determinations of blood and urine
For biochemical determinations of blood, subjects were
asked to fast for 8–10 hours on the night prior to meas-
urement. Study measurements were performed by the
hospital medical laboratory (certified ISO15189) using
standard methods. The glycated hemoglobin (HbA1C)
(CV< 3.0%) was measured by ion-exchange chromatog-
raphy (BioRad Variant, Hercules, California, USA).
Serum magnesium, albumin, lipids, urea nitrogen, cre-
atinine, high-sensitivity CRP (hsCRP), microalbumin
using a Dimension RxL autoanalyzer (Siemens, Newark,
USA). Serum magnesium (CV< 3.0%) was measured
using the methylthymol blue method. Serum albumin
(CV< 2.0%) was estimated using the bromcresol purple
method. Lipids [total cholesterol (CV< 3.0%), HDL (CV
< 4.0%), LDL (CV< 4.0%), triglyceride (CV< 3.0%)]
were assessed using standard enzymatic methods. The
high-sensitivity C-reactive protein (hsCRP) (CV< 3.0%)
was measured by particle enhanced turbidimetric im-
munoassay. The levels of creatinine (CV< 2%) in urine
and serum were used the alkaline picrate-kinetic method.
Blood urea nitrogen (CV< 3.0%) was measured using the
methylthymol blue method. Estimated glomerular filtra-
tion rate (eGFR) was calculated as eGFR (mL/min/
1.73 m2) (Simplified Modification of Diet in Renal Dis-
ease (MDRD)) = 186× serum creatinine-1.154 ×Age-0.203 in
men, and 186× serum creatinine-1.154× Age-0.203× 0.742
in women according to the formula recommended by the
Taiwan Society of Nephrology.
Anthropometric measurements
Anthropometric measurements included height, weight,
blood pressure, waist circumference (WC) and body fat
percentage. As for blood pressure measurement, prior to
measurement, the subject removed any clothing in the
arm area and was left to rest for five minutes to avoid
stimulation. A mercury sphygmomanometer was used,
which was held at the same height as the arm and heart
during measurement, with palms facing upward. Per-
centage of body fat was estimated with bioelectrical im-
pedance analysis using TBF-410 (TANITA, Tokyo,
Japan). Body mass index (BMI) was also calculated in
weight (kg)/height (m2).
Table 1 Characteristics of 210 elderly patients with type
2 diabetes
Variables Mean ± SD n (%)




Diabetes duration (y) 10.9 ± 7.6
Diabetes medication
Oral hypoglycemic drug 147 (70.0)
Insulin and Oral hypoglycemic drug 63 (30.0)
Dietary intake
Energy intake (kcal/kg) 26.0 ± 7.8
Protein intake (g/kg) 0.8 ± 0.3
Magnesium intake (mg/kg) 3.6 ± 1.7
Magnesium intake < DRI 186 (88.6)
Serum magnesium (mmol//L) 0.78 ± 0.09
Hypomagnesaemia ( < 0.75 mmol//L) 78 (37.1)
Serum albumin (g/dL) 4.0 ± 0.3
1. Taiwan DRI (dietary reference intakes, DRI) of magnesium for health
individuals above 19 years of age is 360 mg/d for males and 315 mg/d for
females.
2. Categorical variables were analyzed according to frequency distribution and
expressed in number and percentages [n (%)].
3. Continuous variables were presented as mean values and standard
deviation (Mean ± SD).
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anthropometric measurements
Clinical criteria for blood, urine and anthropometric
measurements were defined the following ranges: 1)
patients with hypomagnesaemia, defined as serum mag-
nesium< 0.75 mmol/L [22]; 2) goals of glycemic, lipid
and blood pressure control recommend as HbA1C
< 7.0%, HDL-cholesterol> 50 mg/dL in females and
> 40 mg/dL in males, triglyceride <150 mg/dL and blood
pressure< 130/80 mmHg [28]; 3) WC has set at ≧
80 cm for men or ≧ 90 cm for women were categorized
as abdominal adiposity. Body fat percentages >30% for
females and >25% for males were categorized as obese.
BMI value for elderly people exceeding 27 results in dra-
matically elevated mortality risk of diabetes [37]. 4) the
diagnosis of metabolic syndrome was made following
either the National Cholesterol Education Program-Adult
Treatment Panel (NCEP-ATPIII) or the International
Diabetes Federation (IDF) criteria. According to both sets
of criteria, metabolic syndrome is present when at least
three of five conditions (abdominal adiposity, hypergly-
cemia, reduced HDL- cholesterol, elevated triglyceride,
and increased arterial blood pressure) are satisfied [38];
5) hsCRP levels of <1, 1 to 3, and >3 mg/L be used to
represent lower, moderate, and higher vascular risk [39];
and 6) stages of chronic kidney disease (CKD) were
defined as follows: stage 1 (eGFR ≥ 90 mL/min/1.73 m2);
stage 2 (eGFR 60–89 mL/min/1.73 m2); stage 3 (eGFR
30–59 mL/min/1.73 m2); stage 4 (eGFR 15–29 mL/min/
1.73 m2); and stage 5 (eGFR <15 mL/min/1.73 m2) [40].
Statistical analysis
Data were analyzed by 2-tailed t-test and one-way
ANOVA for continuous variables and frequency distribu-
tion for categorical variables. Correlation of magnesium
intake levels with metabolic parameter, body fat percent-
age and body mass index were examined in multiple linear
regression analysis. Tests for linear trend were conducted
by using the statement contrast in linear regression mod-
els. Logistic regression models were used to examine the
relationship between magnesium intake levels with de-
pression, metabolic risk factors, high body fat percentage
and high body mass index status. Data are expressed as
odds ratios and 95% CIs. Tests for linear trend were con-
ducted by modeling the odds of each quartile -defined cat-
egory of magnesium intake as a continuous variable in
logistic regression models. All statistical procedures were
performed using SPSS (version 17.0) statistical software,
(SPSS Inc., Chicago, IL, USA), and a p-value of 0.05 was
considered statistically significant.
Results
The clinical characteristics of the elderly patients with
type 2 DM are shown in Table 1. Of the 210 patients,88.6% had magnesium intake less than the dietary refer-
ence intake (DRI), and 37.1% had hypomagnesemia
(serum magnesium< 0.75 mmol/L). Magnesium intake
and serum magnesium by dietary intake, physical activity
level, depression, metabolic parameters, body fat percent-
age, BMI, hsCRP and eGFR status are shown in Table 2.
Lower intake of energy and protein were significantly
associated with lower magnesium intake (p< 0.001). The
low physical activity group displayed lower magnesium
intake than those of the moderate and high physical ac-
tivity group (p= 0.002). However, the high physical activ-
ity group displayed lower serum magnesium levels than
those of the moderate physical activity group (p= 0.024).
Compared with non-depressed patients, depression
patients consumed significantly lower magnesium intake
(p= 0.001). Mean magnesium intakes were significantly
lower in patients with low HDL (p< 0.001), central obes-
ity (p= 0.051), high body fat percent (p= 0.000) and high
BMI (p< 0.001). Compared with non- metabolic syn-
dromes patients, patients with metabolic syndromes dis-
played significantly lower magnesium intake (p= 0.013).
Estimated GFR showed marginal positivity relationships
with magnesium intake (p= 0.067). Magnesium intake
was not significantly correlated with serum albumin,
HbA1C, blood pressure, triglyceride or hsCRP. However,
Table 2 Magnesium intake and serum magnesium by
dietary intake, physical activity level, depression,
metabolic parameter, body fat percentage, body mass
index, hsCRP and estimated GFR status






Energy intake (kcal/kg) 0.000 0.636
< 25 109 2.8 ± 1.3 ab 0.77 ± 0.10
25 to 30 47 4.0 ± 1.2 a 0.79 ± 0.10
>30 54 4.6 ± 2.0 b 0.79 ± 0.08
Protein intake (g/kg) 0.000 0.172
< 0.8 115 2.9 ± 1.3 ab 0.77 ± 0.10
0.8 to 1.0 48 3.7 ± 1.2 ac 0.80 ± 0.09
>1.0 47 5.0 ± 2.0 bc 0.79 ± 0.08
Physical activity level 0.002 0.024
Low 48 2.8 ± 1.4 a b 0.79 ± 0.11
Moderate 83 3.8 ± 1.7 a 0.80 ± 0.09 c
High 79 3.8 ± 1.7 b 0.76 ± 0.08 c
Depression (DSM-IV) 0.001 0.554
< 5 symptoms 147 3.8 ± 1.7 0.78 ± 0.10
≧ 5 symptoms 63 3.0 ± 1.4 0.78 ± 0.09
Metabolic parameters
HbA1c (%) 0.709 0.558
< 7.0 103 3.6 ± 1.6 0.79 ± 0.08
≧ 7.0 107 3.5 ± 1.7 0.78 ± 0.11
HDL-cholesterol (mg/dL) 0.051 0.659
≧ 40 for men or ≧ 50
for women
114 3.8 ± 1.8 0.78 ± 0.09
< 40 for men or< 50
for women
96 3.3 ± 1.5 0.78 ± 0.10
Triglycerides (mg/dL) 0.452 0.456
< 150 172 3.6 ± 1.7 0.78 ± 0.10
≧ 150 38 3.4 ± 1.4 0.79 ± 0.08
Blood pressure (mmHg) 0.344 0.669
Systolic BP< 130 /
Diastolic BP< 80
64 3.7 ± 2.0 0.79 ± 0.09
Systolic BP ≧ 130 /
Diastolic BP ≧ 80
146 3.5 ± 1.5 0.78 ± 0.10
Waist circumference (cm) 0.000 0.687
< 80 for men or< 90
for women
44 4.6 ± 2.2 0.78 ± 0.10
≧ 80 for men or ≧ 90
for women
166 3.3 ± 1.4 0.78 ± 0.09
Metabolic syndrome 0.013 0.234
< 3 components 54 4.2 ± 2.3 0.80 ± 0.10
≧ 3 components 156 3.3 ± 1.4 0.78 ± 0.09
Body Fat percentage (%) 0.000 0.873
< 25 for men or< 30
for women
101 4.0 ± 1.9 0.78 ± 0.09
Table 2 Magnesium intake and serum magnesium by
dietary intake, physical activity level, depression,
metabolic parameter, body fat percentage, body mass
index, hsCRP and estimated GFR status (Continued)
≧ 25 for men or ≧ 30
for women (obese)
109 3.1 ± 1.4 0.78 ± 0.10
Body mass index (kg/m2) 0.000 0.803
< 27 151 3.9 ± 1.7 0.78 ± 0.10
≧ 27 (obese) 59 2.8 ± 1.3 0.78 ± 0.09
High-sensitivity CRP (mg/L) 0.246 0.186
< 1 Low risk 57 3.9 ± 1.9 0.76 ± 0.10
1 to 3 Moderate risk 105 3.5 ± 1.6 0.79 ± 0.10
> 3 High risk 35 3.3 ± 1.5 0.80 ± 0.08
Estimated GFR(ml/min) 0.067 0.363
≧ 90 CKD stage 1 30 4.0 ± 1.7 0.76 ± 0.10
60 - 89 CKD stage 2 121 3.6 ± 1.8 0.79 ± 0.09
30 - 59 CKD stage 3 59 3.1 ± 1.4 0.78 ± 0.11
1. Abbreviations: HbA1C, glycated hemoglobin; HDL, high-density lipoprotein;
BP, blood pressure; CRP, C-reactive protein; GFR, glomerular filtration rate;
CKD, chronic kidney disease.
2. The t test was used for the difference in the means of two groups. The
means of more than two groups were compared using one-way ANOVA
followed by Scheffe’s multiple comparisons test. a-a, b-b, c-c indicates significant
difference between two groups. Data are means ± SD. Significant difference
(p< 0.05).
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with other variables.
Simple linear regression was applied to determine the
relationship of magnesium intake to serum magnesium,
nutritional variables, metabolic parameters, body fat per-
cent, body mass index, hsCRP, and eGFR. Serum magne-
sium levels were not significantly correlated with
magnesium intake. Magnesium intake had positive asso-
ciation with energy intake (r 0.520; p= 0.000) and pro-
tein intake (r 0.646; p= 0.000). A borderline positive
relationship was observed between magnesium intake
and serum albumin (r 0.117; p= 0.092). Furthermore,
magnesium intake was positively correlated with HDL
(r 0.192; p= 0.005). Magnesium intake had significant
inverse relationships with triglyceride (r - 0.144;
p= 0.037) and WC (r - 0.243; p= 0.000). Magnesium
intake showed marginal inverse associations systolic
blood pressure (r - 0.123; p= 0.074) and diastolic blood
pressure (r - 0.128; p= 0.065). However, there was no
significant relationship between magnesium intake and
HbA1C. In addition, magnesium intake had an inverse
relationship with body fat percentage (r - 0.149; p= 0.031)
and BMI (r – 0.289; p= 0.000). A marginal positive rela-
tionship were observed between magnesium intake and
eGFR (r 0.126; p= 0.068). No significant relationship
was found between magnesium intake and hsCRP.
These data were also analyzed and stratified by sex
(data not shown). The information remains about the
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was significantly associated with lower intake of energy
and protein and high body mass index (p< 0.05). High
physical activity demonstrated lower serum magne-
sium levels in men and female (p< 0.05). In addition,
man and female were similar to unstratified analysis
that serum magnesium was not significantly corre-
lated with energy intake, protein intake, and eGFR,
metabolic parameter, body fat percentage and body
mass index. For the elderly men with Type 2 diabetes,
magnesium intake was significantly lower in patient
with metabolic syndrome (0.022). Physical activity
level was significantly associated with magnesium in-
take in men (p = 0.010). However, physical activity
level were not significantly associated with magnesium
intake in female (p= 0.218). For the elderly female
with Type 2 diabetes, magnesium intake was signifi-
cantly lower in patient with depression (p = 0.003).
Central obesity showed marginal inverse relationships
with magnesium intake (p= 0.056).
Adjusted mean of metabolic parameters, body fat per-
centage and body mass index and adjusted Odd ratio of
depression and metabolic risk factors by quartile of mag-
nesium intake after controlling confounding factors are
shown in Table 3. Adjusted mean of HDL was signifi-
cantly higher with increasing quartile of magnesium in-
take (p for trend= 0.006). In addition, adjusted mean of
waist circumference, body fat percentage, and body mass
index were significantly lower with increasing quartile of
magnesium intake (p for trend< 0.001). The adjusted
mean of systolic blood pressure was marginal linear
trend with quartile of magnesium intake (p for trend
< 0.089). The adjusted mean of triglyceride and diastolic
blood pressure was not significantly linear trend with
quartile of magnesium intake, but the adjusted mean of
triglyceride and diastolic blood pressure were lower with
increasing quartile of magnesium intake (p for trend
< 0.120). The odds of depression, central obesity, high
body fat percentage, and high body mass index were sig-
nificantly lower with increasing quartile of magnesium
intake (p for trend <0.005). Although the odds of low
HDL and metabolic syndrome was not significantly lin-
ear trend with quartile of magnesium intake, the odds of
low HDL and metabolic syndrome were lower with in-
creasing quartile of magnesium intake (p for trend
< 0.165). In addition, adjusted mean of metabolic para-
meters, body fat percentage and body mass index and
adjusted Odd ratio of depression and metabolic risk fac-
tors was not significantly correlated with levels of serum
magnesium.
Discussion
Our data suggest that (1) the majority of elderly type 2
diabetes patients may have low magnesium intake; (2)about one-third of elderly diabetes patients had hypo-
magnesaemia; (3) low magnesium intake was associated
with metabolic abnormalities and depression; (4) magne-
sium intake was related to high physical activity level
and demonstrated lower serum magnesium levels. How-
ever, serum magnesium was not significantly associated
with metabolic parameters.
In general, dietary magnesium does not meet the DRI
for elderly subjects and may be prone to chronic latent
magnesium deficiency [41,42]. Daily magnesium intake
for males and females above 50 years of age was 326 mg
and 255 mg, respectively, in the United States. Further-
more, 60-62% of middle-aged to elderly people do not
meet the DRI for magnesium [42]. The average magne-
sium intake for male and female elders was 279 mg and
227 mg, respectively, according to data from the Nutri-
tion and Health Surveys in Taiwan [41]. These data indi-
cated that they are at least 87% of the population in
Taiwan do not meet the DRI for magnesium. In our
data, daily consumption of magnesium in male and fe-
male elderly type 2 DM patients was only 253 mg and
189 mg magnesium, respectively. This indicates that 89%
of our patients do not meet the DRI for magnesium.
It is generally accepted that magnesium deficiency is
closely related to metabolic syndromes. Increased dietary
magnesium intake and/or magnesium supplementation
may improve metabolic syndromes and type 2 DM
[14,25]. Our data also revealed that lower magnesium in-
take was correlated with metabolic syndromes. It affects
HDL, triglyceride, WC, BMI, and body fat percentage. In
addition, systolic and diastolic blood pressure showed
marginal inverse relationships with magnesium intake.
The overall prevalence of metabolic syndromes in these
rural-dwelling elderly type 2 DM patients was 74%
which was much higher than rates reported in two pre-
vious studies on healthy older adults (40%) [14,43].
However, the relationships of magnesium intake with
blood glucose and lipids were inconsistent. Thus,
increased magnesium intake may improve metabolic
control in patients with metabolic syndromes.
Depression is the fourth-leading cause of disability
worldwide according to the World Health Organization
[44]. Prevalence rates of depression are between 5% and
10% [45], whereas it is estimated to be about 12% to
18% in patients with diabetes [46]. Moreover, 31% of eld-
erly diabetes was found to have severe depressive symp-
toms [47]. This finding was confirmed and 30% of
elderly diabetes patients had depression, particularly in
those with low magnesium intake. Indeed, magnesium
deficiency has been independently associated with de-
pressive symptoms [13]. A recent randomized, equiva-
lent trial suggests that oral magnesium supplementation
is as effective as imipramine in the treatment of
depressed elderly diabetes with hypomagnesemia [20].
Table 3 Adjusted mean of metabolic parameters, body fat percentage and body mass index and adjusted Odd ratio of
depression and metabolic risk factors by quartile of Mg intake
Variables Quartile of Mg intake P for
Q1 (n = 52) Q2 (n =53 ) Q3 (n =52 ) Q4 (n =53 ) trend
Quartile range of Mg intake (mg/kg) < 2.3 2.3 - 3.2 3.3 - 4.4 ≧4.5
Mean Mg intake (mg/kg) 2 1.8 ± 0.4 2.8 ± 0.3 3.7 ± 0.3 5.8 ± 1.4 <0.001
Adjusted mean 3
Metabolic parameters*
HbA1c (%) 7.3 ± 1.5 7.5 ± 1.5 7.2 ± 0.9 7.2 ± 1.2 0.838
HDL-cholesterol (mg/dL) 45.3 ± 11.7 44.4 ± 10.2 47.5 ± 13.3 50.6 ± 12.9 0.006
Triglycerides (mg/dL) 113.0 ± 51.3 113.5 ± 77.5 106.4 ± 15.4 92.0 ± 48.8 0.104
Systolic BP 137.1 ± 15.3 136.2 ± 14.7 135.4 ± 15.4 132.9 ± 13.7 0.089
Diastolic BP 78.6 ± 14.4 77.6 ± 11.7 77.8 ± 14.4 74.9 ± 12.5 0.117
Waist circumference (cm) 95.6 ± 9.4 92.9 ± 8.0 91.0 ± 9.9 88.8 ± 8.1c <0.001
Body Fat percentage (%)* 33.0 ± 10.8 29.4 ± 9.0 28.8 ± 6.8 24.5 ± 8.5 <0.001
Body mass index (kg/m2) * 27.2 ± 4.3 25.3 ± 3.4 25.1 ± 3.3 23.6 ± 3.0 <0.001
Adjusted Odds ratio 4
Depression (DSM-IV)≧5 symptoms † 1.00 0.37 (0.16-0.88) 0.44 (0.19-1.02) 0.22 (0.08-0.57) 0.003
Metabolic parameters*
HbA1c (%)≧7.0 1.00 1.01 (0.41-2.50) 1.33 (0.53-3.33) 0.95 (0.34-2.66) 0.907
HDL-cholesterol (mg/dL)< 40 for men
or< 50 for women
1.00 1.33 (0.57-3.10) 0.99 (0.41-2.36) 0.54 (0.20-1.44) 0.162
Triglycerides (mg/dL)≧150 1.00 1.51 (0.49-4.65) 1.91 (0.61-5.99) 0.90 (0.23-3.48) 0.963
Systolic BP≧130 /Diastolic BP≧80 1.00 0.84 (0.34-2.09) 1.04 (0.40-2.73) 0.60 (0.21-1.70) 0.452
Waist circumference (cm) ≧80 for men
or ≧90 for women
1.00 0.41 (0.11-1.54) 0.57 (0.14-2.27) 0.09 (0.02-0.37) 0.001
Metabolic syndrome 1.00 2.10 (0.73-6.06) 1.68 (0.60-4.70) 0.49 (0.17-1.43) 0.153
Body fat percentage (%)≧25
for men or ≧30
for women (obese) *
1.00 0.80 (0.32-2.05) 0.55 (0.21-1.44) 0.21 (0.07-0.61) 0.004
Body mass index (kg/m2)≧27 (obese) * 1.00 0.63 (0.26-1.53) 0.21 (0.07-0.61) 0.09 (0.02-0.35) <0.001
1. Abbreviations: Mg, magnesium; HbA1C, glycated hemoglobin; HDL, high-density lipoprotein; BP, blood pressure.
2. The means of four groups were compared using one-way ANOVA. Data are means ± SD. Significant difference (p< 0.05).
3. Correlation of Mg intake levels with metabolic parameters, body fat percentage and body mass index were examined in multiple linear regression analysis. Data
are adjusted mean ± standard error (SE). Tests for linear trend were conducted by using the statement contrast in linear regression models. Statistically significant
at p <0.05.
4. Logistic regression models were used to examine the relationship between Mg intake levels with depression, metabolic risk factor, high body fat percentage
and high body mass index status. Data are odds ratios (95% CIs). Tests for linear trend were conducted by modeling the odds of each quartile-defined category of
magnesium intake as a continuous variable in logistic regression models. Statistically significant at p <0.05.
5. confounding factors.
* indicates adjusted for sex, age, physical activity level, total energy intake (kcal/day), carbohydrate intake (% of energy), protein intake (% of energy), total fat
intake (% of energy), smoking, and alcohol consumption.
† indicates adjusted for sex and age.
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sium supplementation for elderly patients with diabetes
may benefit the treatment of depression.
A review study indicated that 14-48% of diabetes
suffered from hypomagnesaemia [48]. In the present
study, the prevalence of hypomagnesaemia was about
37%. In addition, we found that magnesium intake had a
significant positive relationship with energy intake and
protein intake. Moreover, lower intake of energy and
magnesium was correlated with a higher prevalence ofhypomagnesemia. In the present study, prevalence of
hypomagnesemia for the energy intake< 25 kcal/kg,
25–30 kcal/kg, and> 30 kcal/kg groups were 40%, 36%,
and 32%, respectively. Likewise, lower intake of protein
and magnesium was associated with a higher prevalence
of hypomagnesemia. Prevalence of hypomagnesemia for
the protein intake< 0.8 g/kg, 0.8-1.0 g/kg and> 1.0 g/kg
groups were 43%, 27%, and 34%, respectively. However,
89% of the elderly diabetes patients had a magnesium
intake which was less than the DRI, however, the
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fore, more than 50% of our patients with a magnesium
intake less than the Taiwan DRI could not be iden-
tified as hypomagnesemia (low serum magnesium
<0.75 mmol/L). Therefore, our results revealed that
serum magnesium was not correlated well with meta-
bolic parameters and depression as shown in a previous
study [49]. Many studies showed that low magnesium in-
take is associated with certain degrees of diabetes risk,
metabolic control and cardiovascular diseases. Serum
magnesium may not be a good marker and may be in-
accurate to correlates with magnesium status. However,
hypomagnesemia could indicate a higher possibility of
critical situations associated to diabetes, metabolic syn-
dromes or cardiovascular diseases. Future clinical trials
need to reveal relationships of serum magnesium, intra-
cellular magnesium levels with various diseases.
The relationship between magnesium status and phys-
ical activity has received much attention in the past dec-
ade [11]. Our data clearly indicated that the low physical
activity group had lower magnesium intake. Magnesium
intake was about the same in the high and moderate
physical activity groups. However, the high physical ac-
tivity group had a significantly lower serum magnesium
levels. In our data, prevalence of hypomagnesemia in the
low, moderate and high physical activity groups were
27%, 31% and 49% respectively. Obviously, the high
physical activity groups also had a significantly higher
prevalence of hypomagnesemia when compared with
that in other two physical activity groups. Thus, high in-
tensity physical activity with inadequate magnesium in-
take seems to increase the risk of hypomagnesemia. This
may be partly due to increased magnesium loss in per-
spiration (especially when working or exercising in hot
environments) and in urine [50]. This could result in
increased magnesium excretion and might increase the
need for higher magnesium intake. When magnesium
intake is insufficient, physical activity will exacerbate the
magnesium deficiency [51]. Increased dietary magne-
sium intake or magnesium supplementation has benefi-
cial effects on physical performance in magnesium-
deficient individuals [52,53]. Hence, for elderly diabetes
patients with high physical activity and low serum mag-
nesium, it is necessary to increase dietary magnesium in-
take or magnesium supplementation.
There were several limitations of this study. First, the
analyses were highly dependent on self-reported dietary
intake and lifestyle data. Overestimation, underestima-
tion, and poor recall might therefore have confounded
the results. Fortunately, these elderly DM patients lived
in rural areas and mostly of them had a simple lifestyle
and eating patterns. The use of traditional quantitative
tools, food models, food pictures and photos helped
these elderly patients to recall the amount of consumedfood and may also increase the effectiveness of the 24-
hour recall. Moreover, questionnaires were also used to
valid dietary patterns during the previous week. Second,
serum magnesium may not be sufficient for indicating
magnesium deficiency [21]. Therefore, the majority of
patients (>89%) with less than the DRI magnesium in-
take were not identified as magnesium deficiency from
their serum magnesium levels. Further investigation will
be warranted.
Conclusions
Majority of elderly diabetes patients have low magne-
sium intake and may exacerbate metabolic abnormal-
ities and depression. Clinical care should therefore
focus on increasing dietary magnesium intake or mag-
nesium supplementation to improve metabolic control,
depression, and physical performance in elderly dia-
betes patients.
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